Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies.

Many liquid formulations for monoclonal antibodies (MAbs) require the final ultrafiltration/diafiltration step to operate at high protein concentrations, often at or above 100 g/L. When operating under these conditions, the excipient concentrations and pH of the final diafiltered retentate are frequently not equal to the corresponding excipient concentrations and pH of the diafiltration buffer. A model based on the Poisson-Boltzmann equation combined with volume exclusion was extended to predict both pH and excipient concentrations in the retentate for a given diafiltration buffer.

Predictive chromatographic simulations for the optimization of recovery and aggregate clearance during the capture of monoclonal antibodies.

Predictive chromatographic simulations were used to assess whether significant aggregate clearance, in addition to high step recovery and limited eluate pool volumes, can be achieved during protein A affinity chromatography capture steps. Such aggregates of the antibody monomer are commonly found in manufacturing processes. A lumped desorption-kinetic limiting model was used to describe the elution from the chromatography column, as batch isotherm measurements indicated no adsorption under elution conditions.

Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.

Diafiltration of a protein solution into a new buffer is a common final step in biopharmaceutical manufacturing. However, the excipient concentrations in the retentate are not always equal to their corresponding concentrations in the new buffer (diafiltration buffer). This phenomenon was observed repeatedly during diafiltration of different therapeutic monoclonal antibodies in which the concentrations of histidine and either sorbitol or sucrose (depending on which was chosen for the diafiltration buffer) in the retentate were lower than in the diafiltration buffer.

Development and application of an automated, low-volume chromatography system for resin and condition screening.

A small-volume chromatography system was developed for rapid resin and parameter screening and applied to the purification of a therapeutic monoclonal antibody from a key product-related impurity. Accounting for constraints in peripheral volume, gradient formation, column integrity, and fraction collection in microtiter plates, the resulting system employed 2-mL columns and was successfully integrated with plate-based methods for rapid sample analysis (e. g.